Glutathionyl haemoglobin is not increased in diabetes nor related to glycaemia, complications, dyslipidaemia, inflammation or other measures of oxidative stress

Diabetes Research and Clinical Practice

Volumn 80, Issue 2, 2008, Pages

  Hoffmann, Peter ^a,b   Woon, Jade ^a,c   Rowley, Kevin G ^c   Karschimkus, Connie ^c   Nelson, Craig L ^c   Dragicevic, George ^c   O'Neal, David ^c   Wilson, Andrew ^c   Croft, Kevin D ^d   Mori, Trevor A ^d   Kemp, Bruce E ^a,e   Best, James D ^c   Jenkins, Alicia J ^c  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e CSIRO   (Australia)

Author keywords

Clinical research; Diabetes; Glutathionyl haemoglobin; Haemoglobin; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLUTATHIONYL HEMOGLOBIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; LIPID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RISK ASSESSMENT; RISK FACTOR;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; GLUTATHIONE; HEMOGLOBINS; HUMANS; INFLAMMATION; OXIDATIVE STRESS;

EID: 41749084823     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.01.012     Document Type: Article

References (12)

1. Jenkins A.J., Best J.D., Klein R.L., and Lyons T.J. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab. Res. Rev. 20 5 (2004) 349-368
2. Bursell S.E., and King G. The potential use of glutathionyl haemoglobin as a clinical marker of oxidative stress. Clin. Chem. 46 (2000) 145-146
3. Niwa T., Naito C., Mawjood A., and Imai K. Increased glutathionyl haemoglobin in diabetes mellitus and hyperlipidaemia demonstrated by liquid chromatography/electrospray ionization-mass spectrometry. Clin. Chem. 46 (2000) 82-88
4. Wilson A.M., O'Neal D., Nelson C.L., Prior D.L., Best J.D., and Jenkins A.J. Comparison of arterial assessments in low and high vascular disease risk groups. Am. J. Hypertension 17 (2004) 285-291
5. Sampathkumar R., Balasubramanyam M., Sudarslal S., Rema M., Mohan V., and Balaram P. Increased glutathionylated haemoglobin (HbSSG) in T2D subjects with microangiopathy. Clin. Biochem. 38 10 (2005) 892-829
6. Al-Abed Y., VanPatten S., Li H., Lawson J.A., FitzGerald G.A., and Manogue K.R. Characterization of a novel haemoglobin-glutathione adduct that is elevated in diabetic patients. Mol. Med. 7 (2001) 619-623
7. Naito C., and Niwa T. Analysis of glutathionyl haemoglobin levels in diabetic patients by electrospray ionization liquid chromatography-mass spectrometry: effect of vitamin E administration. J. Chromatogr. 746 (2000) 91-94
8. Romney J., and Lewanczuk R. Vascular compliance is reduced in the early stages of T1D. Diabetes Care 24 (2001) 2102-2106
9. Naito C., Kajita M., and Niwa T. Determination of glutathionyl haemoglobin in hemodialysis patients using electrospray ionization liquid chromatography-mass spectrometry. J. Chromatogr. B 731 (1999) 121-124
10. Takayama S., Tsutsui S., Horie M., Shimokata K., and Niwa T. Glutathionyl haemoglobin in uremic patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int. 59 Suppl. 78 (2001) 155-158
11. Barter P., and Rye K. High density lipoproteins and coronary heart disease. Atherosclerosis 121 (1996) 1-12
12. Leinonen E., Hurt-Camejo E., Wiklund O., Hulten L.M., Hiukka A., and Taskinen M.R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in T2D. Atherosclerosis 166 (2003) 387-394